Inventiva S.A. - American Depos
IVA
Positions held
Your positionsIVA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $784.25M | Enterprise value | $757.11M | Trailing P/E | — | Forward P/E | -4.42 |
| PEG | — | Price / book | -19.36 | Beta | 1.00 | Dividend yield | 0.00% |
| Revenue growth | -76.7% | Earnings growth | — | Gross margin | 78.3% | Operating margin | -53.4% |
| Profit margin | 0.0% | ROE | -9.9% | ROA | -42.7% | Debt / equity | 2.35 |
| Current ratio | 3.81 | Free cash flow | -$116.12M | Analyst recommendation | strong_buy | Mean target | $15.20 |
| 52w high | $7.98 | 52w low | $3.11 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.5M | $9.2M | $17.5M | $12.2M | — |
| Op margin | -2964.2% | -1021.8% | -587.4% | -466.8% | — |
| Net income | -$354M | -$184M | -$110M | -$54.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$133M | -$94.0M | -$103M | -$56.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
2026-10-04 · Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?
2026-10-04 · Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
2026-10-02 · Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating
2026-09-29 · European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
2026-09-29 · Inventiva (IVA) Q2 2026 Earnings Call Transcript
2026-09-28 · Inventiva Q2 Earnings Call Highlights
2026-09-28 · Sector Update: Healthcare Stocks Lean Lower Premarket Monday
2026-09-28 · Inventiva H1 Loss Narrows
2026-09-28 · Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
2026-09-08 · Inventiva to Present Multiple Abstracts at Paris MASH 2026
2026-09-02 · Inventiva Says All Patients Completed 72-Week Treatment Period in Phase 3 Liver Disease Study
Price (daily)
Full chart · RSI · MACD · patterns